

2nd Announcement:

Health Technology Assessment Tuesday, June 30, 2020, 3-5 pm CET Virtual Webinar

Health Technology Assessment (HTA) is an instrumental part of the process in obtaining reimbursement and market access for pharmaceuticals and medical products in countries around the world.

This webinar will consist of presentations as well as a moderated panel discussion with experts to discuss relevant HTA topics including some of the key challenges that recent scientific advances and new data sources create for different stakeholders.

The Basel Biometric Society (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a scientific meeting on this relevant topic with experts from the pharmaceutical industry, academia and the European HTA bodies.

Program

15:00-15:05	Welcome and Introduction Fred Sorenson, Xcenda
15:05-15:10	Celebrating 10 Years HTA SIG Chrissie Fletcher, GSK UK
15:10-15:30	Health-related quality of life endpoints in benefit assessments: Demands and challenges as seen by IQWiG in Germany Christoph Schürmann, IQWiG
15:30-15:50	Issues related to transparency with HTA dossiers Lara Wolfson, Merck USA
15:50-16:20	An innovative pricing model to assess the price of expensive drugs with an orphan indication Mark Nuijten, A2M and Univ. of Maastricht, NL & ITU, Turkey
16:20-16:55	Moderated Panel Discussion Anja Schiel, Norwegian Medicines Agency, Norway Jens Gröger, Boston Consulting Group Zurich, Univ. of Washington, ISPOR President-elect, Switzerland and USA John Doyle, Pfizer and Columbia Univ. USA
16:55-17:00	Final Summary and Closure of the Meeting



Venue

Free virtual event

Registration

Please register via e-mail to
Fred Sorenson
fred.sorenson@xcenda.com

Questions for the speakers and panel discussion

Please send questions for the
panel discussion to
Roland Marion-Gallois
roland.marion-gallois@bms.com